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Pulmonary rehabilitation after exacerbation
of bronchiectasis: a pilot randomized
controlled trial
James D. Chalmers1,2* , Megan L. Crichton1, Gill Brady1, Simon Finch1, Mike Lonergan1 and Thomas C. Fardon1
Abstract
Background: Pulmonary rehabilitation improves exercise capacity and reduces risk of future exacerbation in COPD
when performed after an exacerbation. There have been no previous studies of post-exacerbation rehabilitation in
bronchiectasis.
Methods: Parallel group randomized controlled trial compared pulmonary rehabilitation (PR) to standard care (SC)
in patients followed an antibiotic treated exacerbation of bronchiectasis. Patients were randomized following a
14 day course of antibiotics was completed. The primary outcome was 6-min walk distance (6 MW) at 8 weeks.
Secondary outcomes were time to the next exacerbation, St.Georges Respiratory Questionnaire, COPD CAT score,
Leicester cough questionnaire (LCQ) and FEV1 at 8 and 12 weeks post exacerbation.
Results: Forty eight patients were enrolled but only 27 had exacerbations within 12 months of enrolment. Nine
patients received pulmonary rehabilitation and 18 received standard care. The 6 MW improved significantly from
post-exacerbation to 8 weeks in both groups, with no significant difference between PR and SC- mean difference of
11 m (95% CI -34.3 to 56.3,p = 0.6). Time to the next exacerbation was not significantly different hazard ratio 0.83
(0.31–2.19, p = 0.7). No significant differences were seen between groups in terms of LCQ, CAT, FEV1 or SGRQ
between groups. An analysis of probability based on the patients enrolled suggested > 1000 subjects are likely be
required to have an > 80% probability of observing a statistically significant difference between PR and SC and any
such differences would be likely to be too small to be clinically relevant.
Conclusions: This pilot study identified no significant benefits associated with pulmonary rehabilitation after
exacerbations of bronchiectasis.
Trial registration: NCT02179983, registered on Clinicaltrials.gov 29th June 2014.
Background
Exacerbations have a major impact on prognosis in
patients with bronchiectasis [1, 2]. Patients with frequent
exacerbations experience a high risk of hospitalization,
have significantly worse quality of life and an increase in
mortality of 86% for patients experiencing 3 or more
exacerbations per year [2, 3].
Exacerbations are inflammatory events that also in-
crease the risk of cardiovascular complications [4, 5].
Exacerbation symptoms last for a median of 16 days and
up to 1 in 5 patients have not recovered symptomatically
35 days after an exacerbation [6]. Forced expiratory
volume in 1 s and peak expiratory flow rate fall at
exacerbation and improve at a variable rate during
recovery leading to reduced physical activity and impair-
ment of quality of life [6, 7]. Physical activity and exer-
cise capacity are key determinants of quality of life in
bronchiectasis and have been most frequently evaluated
using the 6 min walk test [8, 9].
Disease progression in bronchiectasis is associated
with a reduction in exercise capacity. 6-min walk
distance is correlated with lung function and extent of
bronchiectasis on CT scan and was found by McDonnell
et al. to reflect disease severity measured by the
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bronchiectasis severity index [7]. Patients with severe
disease walked an average of 83 m less than patients with
moderate disease and 198 m less than those with mild
disease [7].
Therefore maximising exercise capacity following
exacerbations of bronchiectasis can be seen as prevent-
ing an important element of the disease progression
associated with exacerbations [10–12].
In COPD, it is accepted that performing pulmonary
rehabilitation after exacerbations are acceptable and
highly beneficial [13]. In the systematic review by Puhan
et al., pulmonary rehabilitation reduced future hospital
admissions (OR 0.22 95% CI 0.08–0.58, number needed
to treat = 4) and reduced mortality (OR 0.28 95% CI
0.10–0.84, number needed to treat = 6) with substantial
impacts on quality of life and a mean 6-min walk
distance improvement of 77.7 [13, 14]. For this reason
the use of pulmonary rehabilitation after exacerbations
of COPD is accepted into clinical practice.
Pulmonary rehabilitation has shown benefits in bron-
chiectasis [15]. A recent systematic review by Lee et al.
found 4 trials involing 164 participants which showed an
improvement in incremental shuttle walk distance in
trials in stable patients with improvement in health
related quality of life immediately post intervention
which faded by 6 months [16]. One study of 20 patients
which attempted rehabilitation during hospital admis-
sion was identified but no studies were identified testing
rehabilitation post-exacerbation [17].
The Tayside Rehabilitation in Bronchiectasis Exacerba-
tions (TRIBE) study was designed as a pilot study to
determine potential benefits of rehabilitation following
exacerbations of bronchiectasis.
Methods
The TRIBE study was a parallel group randomized
controlled pilot trial. The study was prospectively regis-
tered at Clinicaltrials.gov- NCT02179983 and is reported
according to CONSORT guidelines. The objective of the
study was to determine the effectiveness of pulmonary
rehabilitation in improving exercise capacity and health
related quality of life following an exacerbation of
bronchiectasis. As a pilot study, it was also intended to
provide information to power a definitive future trial.
The study was approved by the East of Scotland ethics
committee and all patients gave written informed
consent (13/ES/0062).
Inclusion and exclusion criteria and patient enrolment
Patients were enrolled when clinical stable and gave
written informed consent. At enrolment patients agreed
to contact the investigators at the onset of their next
exacerbation.
The inclusion criteria were bronchiectasis confirmed
on High Resolution CT scan; clinically significant
bronchiectasis confirmed by a respiratory physician and
at least one documented exacerbation within the last
year. Patients were required to be independently mobile
and therefore able to undertake pulmonary rehabilitation
if randomized to this arm.
The exclusion criteria were Inability to give informed
consent to participate; age < 18 years; a primary diagnosis
of Chronic Obstructive Pulmonary Disease; significant
comorbidity that would limit the ability to undertake
pulmonary rehabilitation - i.e. Cerebrovascular, cardio-
vascular or musculoskeletal disease; known cystic
Fibrosis; aortic aneurysm; recent myocardial infarction
(within previous year) or unstable angina and patients
having undergone pulmonary rehabilitation in the
previous year.
Exacerbations
Exacerbations were defined as a sustained worsening of
respiratory symptoms for > 48 h and a decision by a
physician that antibiotic therapy is required [18].
EXACT-PRO diaries were used to validate the worsening
of respiratory symptoms, but not as the definition of
exacerbation for inclusion.
After onset of exacerbation patients contacted the
investigators who provided a standardised antibiotic
regimen for 14 days based on prior microbiology results
according to international guideline recommendations
[15]. Patients were then reviewed at day 14 (completion
of antibiotic treatment) and were randomized at day 14
to either intervention or control.
Randomization
Patients were randomized using sealed opaque envelopes
at 1:1 ratio to either pulmonary rehabilitation or stand-
ard care. Standard care consisted of guideline concord-
ant ongoing management including instruction in daily
chest physiotherapy [19, 20].
Pulmonary rehabilitation
Patients randomized to pulmonary rehabilitation re-
ceived a structured rehabilitation programme at Kings
Cross Hospital in Dundee. Each patient was prescribed
an individual programme and joined a group of approxi-
mately ten participants.
There were two supervised sessions per week and two
‘homework’ sessions for a total of 6 weeks. The class
started with a gentle warm up and then moved into their
own individual exercise programme based on their
assessment and personal goals. Each programme con-
tained a mixture of cardiovascular training – e.g. tread-
mill, bike, walking and strength training with free
weights. Patients were exercised at 80% VO2max for
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cardiovascular work and one repetition maximum (RM)
aiming for 8–10 reps for strength. All exercises were
supervised and progressed by specialist physiotherapists
and respiratory nurses. The exercise sessions were
followed immediately by a cool-down, again led by the
physio.
All patients attending the class were also given the fol-
lowing group educational activities; Benefits of exercise;
Relaxed abdominal breathing and controlled breathing;
Chest clearance techniques; Pathology of chronic lung
disease (including bronchiectasis); Practical demo/advice
on inhalers; Medications; Self-management; Smoking
cessation; Pacing and energy conservation; Nutrition;
Welfare rights and benefits; Maintenance options.
All patients received individual instruction in breath-
ing strategies and chest clearance techniques to aid
self-management. At the end of the six-week block of
pulmonary rehab, patients were all encouraged to attend
local maintenance groups including Active for Life (in
local leisure centres) or circuit classes in various
community settings (all supervised).
Endpoints
Endpoints were evaluated at baseline, onset of exacerbation,
end of exacerbation (day 14), 8 weeks post-exacerbation
and 12 weeks post-exacerbation.
The primary outcome was change in 6 min walk test
distance from end of exacerbation (day 14 post
antibiotic) to 8 weeks post-exacerbation.
Six min walk distance at 12 weeks post-exacerbation
was a secondary endpoint. Additional secondary out-
comes were; time to the next exacerbation, quality of life
using the St Georges Respiratory Questionniare at 8 and
12 weeks, spirometry at 8 and 12 weeks, Cough symp-
toms measured using the Leicester cough questionnaire
and COPD CAT questionnaire at 8 and 12 weeks and
sputum microbiology.
As this was a pilot study, an additional objective was
to identify the number of patients that would have to be
recruited to demonstrate a clinically meaningful im-
provement in 6-min walk distance.
Statistical analysis
Statistical analysis was performed using the Graphpad
Prism v6 and R. Categorical variables are presented by
frequencies and percentages and statistical differences
were analysed using χ2 test or Fisher exact test when
required. Continuous variables are presented as mean
and standard deviation (SD) or median and interquartile
range (IQR) when data are not distributed normally.
Mean differences at each time point were compared
using t-tests. As the objective of the study was to power
a definitive future trial, no a priori power calculation
was conducted. To produce estimates of how many
patients would have to be recruited to achieve statisti-
cally significant results a semi-Bayesian approach, using
frequentist tests but interpreting their results as prob-
ability distributions for parameter values, was used.
These allowed for the uncertainty in the means and
standard deviations estimated from the pilot data.
Non-parametric bootstrap resamples of the data were
drawn and used to construct empirical joint distribu-
tions of means and standard deviations. Simulated
datasets of various sizes were then created from these
distributions and used to estimate the probability of
reporting statistically significant differences between
group means for the 6-min walk test that were > 0 m, >
25m, > 54m, for different sample sizes. 25 m and 54 m
were chosen as they are previously described minimum
clinically important differences for the 6-min walk test
[21, 22]. All results are presented for the intention to
treat population with a sensitivity analysis shown exclud-
ing patients with deviations from the protocol (per-pro-
tocol analysis). We defined statistical significance as a
two-tailed p < 0.05 for all analyses.
Results
Fifty one patients were screened and 48 patients were
enrolled at baseline. 62.7% of patient were female and
the median age was 68 years. Twenty seven patients
attended with acute exacerbations and were randomized.
Therefore 56% of patients enrolled could be randomized.
Of those patients not attending within 12months with
exacerbations, 2 withdrew from the study prior to
exacerbation while one patient was withdrawn by the
investigators for failing to report exacerbations. The
other patients did not have exacerbations during the
observation period. The flow of patients through the
study are shown in Fig. 1.
The characteristics of patients enrolled and the
patients randomized in the study are shown in Table 1.
6-min walk distance
The 6-min walk distance improved from post-exacerba-
tion to 8 weeks in both groups, with no significant differ-
ence between pulmonary rehabilitation and standard
care. 6 min walk distance improved by 26 m (− 2 to
54.01) in the pulmonary rehabilitation group and 15
m (− 16.6 to 46.7) in the standard care group. The
mean difference of 11 m (− 34.3 to 56.3), p = 0.6 was
not statistically significant (Fig. 2).
There was similarly no statistically significant differ-
ence in 6 min walk distance at 12 weeks and in fact the
improvement in walking distance was numerically
greater in the standard care group compared to pulmon-
ary rehabilitation (mean difference 4.6 m 95% CI − 59.9
to 50.7, p = 0.9).
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Secondary endpoints
Time to the next exacerbation was not significantly dif-
ferent between the two groups. The median time to next
exacerbation was 169 days in the standard care group
and 190 days in the pulmonary rehabilitation group. The
hazard ratio was 0.83 (95% CI 0.31–2.19, p = 0.7) Fig. 3.
Cough symptoms improved by a mean of 0.83 points
(+/− 1.24) in the pulmonary rehabilitation group com-
pared to 0.91 points (+/− 0.61) in the standard care
group at 8 weeks. The corresponding results at 12 weeks
were 0.82 (+/− 1.1) and 0.51 (+/− 0.51), p = 0.8.
Symptoms measured using the CAT score improved
by 2.1 points (+/− 1.6) in the pulmonary rehabilitation
group and by 0.86 points (+/− 1.9), p = 0.6 at 8 weeks.
Difference in symptoms was even greater at 12 weeks
with an improvement of 2.89 points (+/− 1.9) in the
pulmonary rehabilitation group and a worsening of
symptoms by 0.6 points (+/− 2.5) in the standard care
group. The mean difference of 3.5 points at this time
point substantially exceeded the MCID for this scale but
was not statistically significant (=0.3).
No changes in the St. Georges Respiratory question-
naire were statistically significant across the total score
or the activity, impact or symptom domains (Fig. 4).
FEV1 improved by 100 ml (+/− 56ml) in the pulmon-
ary rehabilitation group compared to 21 ml (+/− 33ml)
in the standard care group at 8 weeks,p = 0.2 with no
difference evidence at 12 weeks (p = 0.4).
Sputum microbiology showed no differences between
groups.
The per-protocol analysis for the primary endpoint
found a mean difference of 24 m (− 28.9 to 76.9 m),
p = 0.4. No significant differences were observed in
any other endpoints in the per protocol analysis. No
safety issues were identified in the study.
Power calculation
The data collected suggested that large differences
between groups exceeding the reported MCIDs of 25 or
54m in the 6- min walk test were unlikely. The prob-
ability of rehab leading to improved outcomes (based on
the estimated mean difference and using a common
standard deviation to calculate the standard error on the
difference between the group means) is 0.77.
This translates into a 17% probability that rehabili-
tation improves mean 6 min walk test by more than
25 m, and a 0.2% chance that the difference is greater
than 54 m.
A full assessment of the probability of the study
producing a statistically significant result for a clinically
meaningful effect size needs to allow for uncertainty in
both the estimate of the difference between the mean
outcomes for the two treatments and the estimated
common standard deviation around those means. It also
needs to respect the correlation between those estimates.
Uncertainty in the proportion completing per protocol
has a smaller effect. The figure below shows that this
probability continues to climb as the sample size in-
creases past 2000, but the only scenario where the prob-
ability reaches 80% occurs when only the per protocol
data is used and any significant difference, no matter
how small, is considered a success. Even under those
conditions, more than 1000 participants would need to
be recruited (Fig. 5).
Discussion
Pulmonary rehabilitation is an established intervention
for the management of multiple respiratory disorders
including COPD, interstitial lung disease and bronchi-
ectasis [15, 23, 24]. For stable patients with bronchi-
ectasis pulmonary rehabilitation has been strongly
Fig. 1 Flow chart of the study
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recommended by the 2017 European Respiratory
Society Guidelines [15]. This was on the basis of a
meta-analysis of 4 trials which each showed consist-
ent benefits in terms of improved exercise capacity,
improved symptoms and in one study, a reduction in
exacerbations [16].
Our study was designed to evaluate whether the bene-
fits of pulmonary rehabilitation would extend to patients
Table 1 Baseline characteristics of the study population
Characteristics Patients enrolled
at baseline
Patients randomized Pulmonary
rehabilitation (PR)
Standard
care (SC)
p-value (comparing
PR vs SC)
N 48 27 9 18
Age (years) 68 (63–72) 68 (63–72) 68 (63–71) 68 (63–73) 0.8
Sex (% female) 31 (64.6%) 20 (74.1%) 5 (55.6%) 15 (83.3%) 0.2
Comorbidities
Angina 4 (8.3%) 1 (3.7%) 0 (0%) 1 (8.3%) 1.0
Myocardial infarction 3 (6.3%) 0 (0%) 0 (0%) 0 (0%) 1.0
Osteoporosis 5 (10.4%) 4 (14.8%) 2 (22.2%) 2 (11.1%) 0.6
Anxiety 7 (14.6%) 5 (18.5%) 2 (22.2%) 3 (16.7%) 1.0
Diabetes 5 (10.4%) 3 (11.1%) 1 (11.1%) 2 (11.1%) 1.0
Hypertension 12 (25.0%) 9 (33.3%) 2 (22.2%) 7 (38.9%) 0.7
Smoking status
Never 31 (64.6%) 18 (66.7%) 7 (77.8%) 11 (61.1%) 0.6
Ex 14 (29.2%) 8 (29.6%) 1 (11.1%) 7 (38.9%)
Current 3 (6.3%) 1 (3.7%) 1 (11.1%) 0 (0%)
Medications
Inhaled corticosteroids 22 (45.8%) 16 (59.3%) 6 (66.7%) 10 (55.6%) 0.7
Macrolide 28 (58.3%) 17 (63.0%) 6 (66.7%) 11 (61.1%) 1.0
Other long term antibiotic 2 (4.2%) 1 (3.7%) 0 (0%) 1 (5.6%) 1.0
Inhaled antibiotic 1 (2.1%) 1 (3.7%) 0 (0%) 1 (5.6%) 1.0
Disease severity
Exacerbations per year
1 14 (29.2%) 4 (14.8%) 2 (22.2%) 2 (11.1%) 0.6
2 8 (16.7%) 8 (29.6%) 4 (44.4%) 4 (22.2%)
3 or more 26 (54.2%) 15 (55.6%) 3 (33.3%) 12 (66.7%)
Body mass index 27.3 (24.1–30.8) 27.7 (24.5–31.5) 30.7 (25.3–33.3) 26.8 (23.1–30.5) 0.3
FEV1 1.79 (1.19–2.11) 1.78 (1.19–2.06) 1.98 (1.10–2.50) 1.71 (1.25–2.05) 0.5
FEV1% predicted 81.5 (53.3–102) 81 (52–96) 76.0 (46.5–109) 83 (55.8–90.8) 0.4
FVC 2.76 (2.25–3.74) 2.69 (2.24–3.34) 2.92 (2.17–3.86) 2.67 (2.18–3.22) 0.5
6-min walk distance (m) 432 (334–497) 434 (348–500) 414 (280–494) 448 (400–507) 0.6
Bronchiectasis severity index
Mild 9 (18.8%) 6 (22.2%) 2 (22.2%) 4 (22.2%) 0.9
Moderate 20 (41.7%) 10 (37.0%) 4 (44.4%) 6 (33.3%)
Severe 19 (39.6%) 11 (40.7%) 3 (33.3%) 8 (44.4%)
Microbiology at baseline
Haemophilus influenzae 17 (35.4%) 9 (33.3%) 3 (33.3%) 6 (33.3%) 1.0
Moraxella catarrhalis 8 (16.7%) 5 (18.5%) 1 (11.1%) 4 (22.2%) 0.6
Enterobacteriaceae 7 (14.6%) 5 (18.5%) 2 (22.2%) 3 (16.7%) 1.0
Pseudomonas aeruginosa 6 (12.5%) 4 (14.8%) 2 (22.2%) 2 (11.1%) 0.6
Others 10 (20.8%) 4 (14.8%) 1 (11.1%) 3 (16.7%) 1.0
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following an exacerbation of bronchiectasis. This was
based, in part, on the observation that pulmonary
rehabilitation after exacerbations of COPD carries
substantial benefits including reduced risk of hospital
admissions and mortality [14].
Our study did not demonstrate significant benefits
associated with pulmonary rehabilitation. 6-min walking
distance and symptoms improved significantly between
the immediate post-exacerbation period and 8 and 12
weeks post-exacerbation, but there were no significant
differences between groups. For the primary outcome of
6-min walk distance in particular, the difference of 11 m
at 8 weeks is unlikely to be clinically meaningful and
there was no benefit of rehabilitation at 12 weeks with
numerically greater improvement in the standard care
group.
Our study was designed as a pilot trial to power a
future larger trial if we found evidence to support the
hypothesis that post-exacerbation rehabilitation was
beneficial. Our analysis of the 27 subjects enrolled deter-
mined that while there is inevitably some uncertainty
about the possible treatment effect given the small num-
ber of subjects enrolled, the variation in rates in recovery
of 6-min walk distance indicated that more than 1000
subjects would need to be enrolled to achieve a > 80%
probability of showing a clinically meaningful effect.
Our data make it unlikely, therefore, that pulmonary
rehabilitation will be beneficial in this population of pa-
tients with exacerbations treated with oral antibiotics.
Our study did not enrol patients with severe exacerba-
tions requiring hospitalization and so does not exclude
the possibility of a treatment benefit in this, or other
populations not included in the present study. Our study
did suggest a clinically meaningful difference, albeit not
statistically significant, in respiratory symptoms mea-
sured by CAT. With such a small sample size it should
be acknowledged that these differences may be the result
of chance but they suggest that symptomatic improve-
ment should be investigated in future trials of recovery
from exacerbations.
Ours is not the only study that has failed to show
benefit of pulmonary rehabilitation post-exacerbation.
Greening et al. studied a cohort of 389 hospitalized
individuals with multiple respiratory diseases including
20 subjects with bronchiectasis [17]. They randomized
patients to early hospital based rehabilitation or standard
care in hospital (within 48 h of hospital admission)
consisting of daily supervised strength and aerobic
training and neuromuscular electrical stimulation. The
early rehabilitation failed to produce any clinical ben-
efits in this trial and mortality was increased in the
group that received rehabilitation at 12 months. The
mechanism for this is unknown but as discussed by
Spruit et al., appeared not be directly related to the
intervention [13, 17].
Important strengths of our study include the well
characterised patient population, the exclusion of pa-
tients with co-existing COPD where the role of pulmon-
ary rehabilitation is established and the use of multiple
Fig. 2 Improvement in 6-min walk distance from randomization at
the end of antibiotic therapy to 8 weeks (primary outcome) and 12
weeks (secondary outcome). Data are presented as mean change
from baseline with standard error
Fig. 3 Kaplain-Meier survival curve showing time to the next exacerbation after randomization
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endpoints to evaluate efficacy. Our study has important
limitations. The sample size is small as this was a pilot
study. The number of subjects enrolled (48) should have
been sufficient to randomize at least 20 subjects to each
arm but despite enriching for a population of patients
with at least 1 exacerbation in the previous 12months
only 27 (56%) patients had an exacerbation during the
subsequent year. This experience is entirely consistent
with recent clinical trials in bronchiectasis. The
RESPIRE trials of inhaled dry powder ciprofloxacin, for
example, enrolled patients with a history of 2 more
exacerbations per year but despite this history of
frequent exacerbations, as many as 67% of patients in
RESPIRE 2 did not experience an exacerbation in the
subsequent year [25–27]. The reasons for this remark-
able discordance between exacerbation reporting prior
to trials and during the course of trials needs to be in-
vestigated in future studies. Randomization results in a
possibility of unequal distribution of patients between
arms in small studies and we experience this problem in
TRIBE. Indeed twice as many subjects were randomized
to the standard care arm as the intervention arm. Never-
theless the power calculations indicate that potentially
thousands of patients would have been required to show
clinically meaningful differences in the study. Our study
was designed prior to the widespread use of the quality
of life bronchiectasis questionnaire and so the SGRQ
Fig. 4 Changes from randomization in the St Georges Respiratory Questionnaire (SGRQ) across the 3 domains and the total score. No differences
were statistically significant between the pulmonary rehabilitation and standard care groups at any time point. Data are presented as mean
change with standard error
Fig. 5 Probability of a significant difference comparing Pulmonary
rehabilitation with standard care. The Y-axis shows the probability of
a positive result and x-axis shows the required sample size. The
colour of lines are as follows BLACK: any difference between groups
is considered meaningful RED = a difference of > 25 m is required,
GREEN = a difference of > 54 m is required. The broken lines indicate
per-protocol analysis with solid lines indicating the intention to
treat population
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and CAT score were used instead. We are aware that
these were not originally designed for bronchiectasis and
future studies should establish if symptoms and quality
of life improve when using bronchiectasis specific tools
[28–30]. Our study was performed prior to the new con-
sensus definition of bronchiectasis exacerbations [18].
Although compliance of those patients randomized to
pulmonary rehabilitation was excellent for the super-
vised visits, we did not monitor adherence to the home
training sessions. Adherence to pulmonary rehabilitation
is suboptimal in clinical practice and so the results of
randomized trials do not always transfer into benefits in
real life.
Conclusion
Our pilot randomized trial identified no statistically
significant improvement in exercise capacity, symptoms
or quality of life with pulmonary rehabilitation after
exacerbations. This pilot data suggests that any benefits
of pulmonary rehabilitation in this setting are likely to
be too small to be clinically meaningful.
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